XML 17 R60.htm IDEA: XBRL DOCUMENT v3.19.3
Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   $ 63,284
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 74,389  
ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   1,214
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) 0 years  
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 0  
Oragenics, Inc. | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   5,810
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) 4 years 8 months 12 days  
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 5,463  
Intrexon Energy Partners, LLC | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   10,267
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) 4 years 6 months  
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 8,362  
Intrexon Energy Partners II, LLC | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   14,060
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) 5 years 2 months 12 days  
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 12,843  
Surterra Holdings, Inc. | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   0
Surterra Holdings, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) 8 years 8 months 12 days  
Surterra Holdings, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 13,987  
Genopaver, LLC | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   1,175
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) 4 years 6 months  
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 789  
Fibrocell Science, Inc. | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   17,519
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) 5 years 1 month 6 days  
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 18,102  
Persea Bio, LLC | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   2,697
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) 5 years 3 months 18 days  
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 3,553  
Harvest start-up entities | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue [1]   7,644
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) [1] 5 years 4 months 24 days  
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue [1] $ 6,993  
Other | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue   $ 2,898
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01    
Contract With Customer, Asset And Liability [Line Items]    
Average remaining performance period (in years) 1 year 8 months 12 days  
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments    
Contract With Customer, Asset And Liability [Line Items]    
Deferred revenue $ 4,297  
[1]
As of September 30, 2019 and December 31, 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.